(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback